Theratechnologies Inc. (THTX)

NASDAQ: THTX · IEX Real-Time Price · USD
1.435
-0.015 (-1.03%)
At close: Jul 12, 2024, 4:00 PM
1.420
-0.015 (-1.05%)
After-hours: Jul 12, 2024, 4:51 PM EDT
-1.03%
Market Cap 65.98M
Revenue (ttm) 60.71M
Net Income (ttm) -5.14M
Shares Out 45.98M
EPS (ttm) -0.10
PE Ratio n/a
Forward PE 8.89
Dividend n/a
Ex-Dividend Date n/a
Volume 56,528
Open 1.430
Previous Close 1.450
Day's Range 1.380 - 1.520
52-Week Range 0.880 - 3.520
Beta 1.78
Analysts Strong Buy
Price Target 12.00 (+736.24%)
Earnings Date Jul 10, 2024

About THTX

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products inc... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 103
Stock Exchange NASDAQ
Ticker Symbol THTX
Full Company Profile

Financial Performance

In 2023, THTX's revenue was 81.76 million, an increase of 2.13% compared to the previous year's 80.06 million. Losses were -23.96 million, -49.28% less than in 2022.

Financial numbers in CAD Financial Statements

Analyst Forecast

According to one analyst, the rating for THTX stock is "Strong Buy" and the 12-month stock price forecast is $12.0.

Price Target
$12.0
(736.24% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024

MONTREAL, July 10, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercia...

4 days ago - GlobeNewsWire

Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update

MONTREAL, June 26, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercia...

18 days ago - GlobeNewsWire

Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors

MONTREAL, May 23, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercial...

7 weeks ago - GlobeNewsWire

Theratechnologies Reports on its Annual Meeting of Shareholders

MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercial...

2 months ago - GlobeNewsWire

Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting

MONTREAL, May 02, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercial...

2 months ago - GlobeNewsWire

Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders

MONTREAL, April 15, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commerci...

3 months ago - GlobeNewsWire

Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

MONTREAL, April 11, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commerci...

3 months ago - GlobeNewsWire

Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024

MONTREAL, April 10, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commerci...

3 months ago - GlobeNewsWire

Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform

MONTREAL, April 08, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commerci...

3 months ago - GlobeNewsWire

Theratechnologies Appoints Elina Tea to its Board of Directors

MONTREAL, April 05, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commerci...

3 months ago - GlobeNewsWire

Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update

MONTREAL, April 03, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commerci...

3 months ago - GlobeNewsWire

Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform

MONTREAL, March 28, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commerci...

3 months ago - GlobeNewsWire

Theratechnologies Announces Update on its Preclinical Oncology Research Program

Company continues to shift to commercial focus as it seeks partners to advance R&D MONTREAL, March 22, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) ...

4 months ago - GlobeNewsWire

Theratechnologies Appoints Jordan Zwick to its Board of Directors

MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commerci...

4 months ago - GlobeNewsWire

Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer

MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commerci...

4 months ago - GlobeNewsWire

Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau

MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercia...

4 months ago - GlobeNewsWire

Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA

MONTREAL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercia...

4 months ago - GlobeNewsWire

Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance

MONTREAL, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercia...

5 months ago - GlobeNewsWire

Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action

MONTREAL, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercia...

5 months ago - GlobeNewsWire

Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer

MONTREAL, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercia...

5 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Theratechnologies Inc. - THTX

NEW YORK , Feb. 7, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Theratechnologies Inc. ("Theratechnologies" or the "Company") (NASDAQ: THTX).  Such investors ar...

5 months ago - PRNewsWire

Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update

MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercia...

5 months ago - GlobeNewsWire

Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA

MONTREAL, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercia...

6 months ago - GlobeNewsWire

Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Application

MONTREAL, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercia...

6 months ago - GlobeNewsWire

Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDA

MONTREAL, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercia...

6 months ago - GlobeNewsWire